Amylyx is proud to announce that the U.S. Food and Drug Administration (FDA) has approved RELYVRIO™ (sodium phenylbutyrate and taurursodiol [also known as ursodoxicoltaurine]), for the treatment of adults with amyotrophic lateral sclerosis (ALS) in the U.S.
More moments
like this
In memory of Mick, a husband and father, who was a gifted tattoo artist and musician.
Everything we do at Amylyx is centered around those living with neurodegenerative diseases. We are on a mission to discover and develop treatments for relentless neurodegenerative diseases and to help support and create more moments for the neurodegenerative disease community.
In memory of Mick, a husband and father, who was a gifted tattoo artist and musician.
And this
Kristina, living with ALS
Kristina, living with ALS
And this
In memory of Eric, a husband and father, who was a courageous skydiver and Army veteran.
Because these are the moments that truly matter.
In memory of Eric, a husband and father, who was a courageous skydiver and Army veteran.
FDA Approves RELYVRIO™ (previously known as AMX0035) for the treatment of adults with ALS in the U.S.
Health Canada Approves ALBRIOZA™ (sodium phenylbutyrate and ursodoxicoltaurine) for the Treatment of ALS
Amylyx is proud to announce that Health Canada has approved ALBRIOZA™ (sodium phenylbutyrate and ursodoxicoltaurine), with conditions, for the treatment of amyotrophic lateral sclerosis (ALS). ALBRIOZA (previously known as AMX0035) is an oral fixed-dose combination therapy that may reduce neuronal cell death in people living with ALS, either as a stand-alone therapy or when added to existing treatments.
In pursuit of more
Our ongoing commitment to discovery carries with it a responsibility to be transparent, set realistic expectations, and work together to make an impact. Learn more about our unique culture, approach to clinical trials and more.
Our ongoing commitment to discovery carries with it a responsibility to be transparent, set realistic expectations, and work together to make an impact. Learn more about our unique culture, approach to clinical trials and more.
Driven by People
“« When you're diagnosed with ALS [amyotrophic lateral sclerosis], you're no longer on the human clock, you're on the ALS clock. Every passing day is a lifetime to an ALS patient, and ALS patients don't have time to wait.” »
Cali, ALS caregiver
“« I feel like Amylyx is a very different company than most that I work with and truly seems like a company that cares, with a big heart, but further than that is they have a fierceness in them and they’re not going to back down from so many of the obstacles that people living with ALS have been facing.” »
Sandy, Person with ALS
“« I believe in Amylyx, I think they are truly patient-centric. They don't talk the talk, they walk the walk.” »
Gwen, Person living with ALS
“« You require help, that in the years prior, you never needed — where people have to change their lifestyle, to make your lifestyle. So, it doesn't just affect you, it affects the ones around you.” »
Greg, Person living with ALS
In the Moment
Latest News
Next
An error has occurred. Please refresh the page and retry.
Keep in touch
To stay up to date on Amylyx news, click subscribe.